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Heterogeneity in VEGFR3 levels drives lymphatic
vessel hyperplasia through cell-autonomous and
non-cell-autonomous mechanisms
Yan Zhang1, Maria H. Ulvmar 1, Lukas Stanczuk1, Ines Martinez-Corral 1, Maike Frye1, Kari Alitalo2 &
Taija Mäkinen1
Incomplete delivery to the target cells is an obstacle for successful gene therapy approaches.
Here we show unexpected effects of incomplete targeting, by demonstrating how hetero-
geneous inhibition of a growth promoting signaling pathway promotes tissue hyperplasia. We
studied the function of the lymphangiogenic VEGFR3 receptor during embryonic and post-
natal development. Inducible genetic deletion of Vegfr3 in lymphatic endothelial cells (LECs)
leads to selection of non-targeted VEGFR3+ cells at vessel tips, indicating an indispensable
cell-autonomous function in migrating tip cells. Although Vegfr3 deletion results in lymphatic
hypoplasia in mouse embryos, incomplete deletion during post-natal development instead
causes excessive lymphangiogenesis. Analysis of mosaically targeted endothelium shows
that VEGFR3− LECs non-cell-autonomously drive abnormal vessel anastomosis and hyper-
plasia by inducing proliferation of non-targeted VEGFR3+ LECs through cell-contact-
dependent reduction of Notch signaling. Heterogeneity in VEGFR3 levels thus drives vessel
hyperplasia, which has implications for the understanding of mechanisms of developmental
and pathological tissue growth.
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B lood and lymphatic vessels play essential roles duringdevelopment and adult tissue homeostasis, as well as invarious diseases1–3. During development and vascular
growth, most blood and lymphatic vessels form by sprouting
from pre-existing vessels through a process termed (lymph)
angiogenesis. Previous studies have established a critical role for
Notch signaling during sprouting angiogenesis in the speciﬁca-
tion of endothelial cells (ECs) to migratory tip cells and pro-
liferating stalk cells that show differential sensitivities and
responses to angiogenic growth factors4. Blood endothelial tip
cells express high levels of the vascular endothelial growth factor
receptor 2 (VEGFR2) and VEGFR3, and upregulate the Notch
ligand delta-like 4 (DLL4)5–8. DLL4 has, in turn, been thought to
induce stalk cell behavior in adjacent ECs by activating Notch
signaling9–11. Recent studies however indicate that activation of
Notch signaling is required in tip cells, and the level of Notch
activity is more important than direct DLL4-mediated cell–cell
communication in controlling EC behavior during sprouting
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Fig. 1 VEGFR3 is indispensable for tip cell function during embryonic dermal lymphatic vessel sprouting. a Schematic of the genetic constructs and 4-OHT
administration schedule (Cre induction, red (6 × 1 mg); estimated effective period (24 h), light red). The timing of dermal lymphatic vessel formation in the
dorsal skin is indicated. b Whole-mount immunoﬂuorescence of E17.5 Vegfr3ﬂox;R26-mTmG;Prox1-CreERT2 skin. Boxed areas are magniﬁed and single
channel images for VEGFR3 staining are shown. Note efﬁcient depletion of VEGFR3 in the Cre-targeted (GFP+) LECs and the presence of non-targeted
cells at the tips of hypoplastic vessel sprouts (arrows) in the mutant (ﬂox/ﬂox) skin. c–g Quantiﬁcation of dermal lymphatic vessel parameters in E17.5
Vegfr3ﬂox;R26-mTmG;Prox1-CreERT2 embryos. Bars represent mean (n= 4–10 embryos, as indicated) ± s.e.m. h, i Whole-mount analysis of E16.5 skin after
mosaic deletion of one (ﬂox/+) or two (ﬂox/ﬂox) Vegfr3 alleles by a single 4-OHT (1 mg) administration at E13.5. j Quantiﬁcation of Cre-targeted (GFP+)
LECs at the dorsal midline (area depicted in i). Bars represent mean (n= 5–6 embryos, as indicated) ± s.e.m. * P < 0.05, *** P < 0.001. Two-tailed unpaired
Student’s t test (c–g, j). Scale bars: 200 µm (b, i). ns: not signiﬁcant
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angiogenesis12,13. Nevertheless, inhibition of DLL4-Notch sig-
naling leads to vascular hypersprouting in vivo9–11. Abnormal
vascular responses leading to excessive sprouting are often
associated with increased EC proliferation. How cell migration
and proliferation are coupled during vascular network formation
is however incompletely understood.
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Fig. 2 Early post-natal deletion of Vegfr3 results in dermal lymphatic vessel hyperplasia during a critical post-natal period of 2 weeks. a Time course analysis
of the effect of post-natal Vegfr3 deletion on dermal lymphatic development. Whole-mount immunoﬂuorescence of ear skin of indicated stages and Tam/
4-OHT treatment regimes. b Quantiﬁcation of Cre-targeted (GFP+, Vegfr3 deleted) LECs in the distal vessel tips in P21 mice treated with Tamoxifen at P2
and P3. Bars represent mean (n= 6 ﬂ/+ and n= 4 ﬂ/ﬂ mice) ± s.e.m. c Quantiﬁcation of vessel branch points in ear skin analyzed in Fig. 2a after indicated
Tam treatment regimes. Tamoxifen administration schedule (Cre induction, red (n × 150 µg); estimated effective period (72 h), light red) (left) is shown.
Bars represent mean (n= 3–5 mice, as indicated) ± s.e.m. d Whole-mount immunoﬂuorescence of ear skin of 5 weeks old mice treated with Tamoxifen at
P2, P4 and P6. e, f Quantiﬁcation of vessel branch points and area in ear skin analyzed in Fig. 2d. Bars represent mean (n= 3–6 mice, as indicated) ± s.e.m.
*P < 0.05, ***P < 0.001, ****P < 0.0001. Two-tailed unpaired Student’s t test (b, c, e, f). Scale bars: 200 µm (a, d). ns: not signiﬁcant
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The key regulator of lymphatic vascular growth and lym-
phangiogenic vessel sprouting is VEGF-C14–17, but the relative
contributions of its two tyrosine kinase receptors VEGFR2 and
VEGFR3 have not been investigated in detail. Here we studied the
function of VEGFR3 during embryonic and post-natal lym-
phangiogenesis using conditional Cre/loxP mediated gene dele-
tion in mice. We found that VEGFR3 is required cell-
autonomously for lymphatic endothelial tip cell function and
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vessel sprouting. Unexpectedly, VEGFR3 downregulation is
coupled to lateral induction of cell proliferation and vessel ana-
stomosis through inhibition of Notch signaling in the neighbor-
ing VEGFR3+ LECs that escaped Cre recombination. These data
uncover a previously unrecognized non-cell-autonomous
mechanism regulating vascular growth.
Results
VEGFR3 is key to lymphatic endothelial tip cell function. To
investigate the cellular mechanisms of lymphatic vessel sprouting,
we genetically deleted Vegfr3 in lymphatic endothelia by crossing
mice carrying conditional Vegfr3ﬂox alleles with Prox1-CreERT2
animals (Fig. 1a). Gene-deleted cells were visualized by simulta-
neous Cre-mediated activation of the green ﬂuorescent protein
(GFP) using the R26-mTmG reporter line. We administered 4-
OHT on six consecutive days starting at E10.5 to ensure efﬁcient
gene targeting (Fig. 1a), which was evidenced by uniform GFP
expression in the lymphatic vessels of control embryos at E17.5
(Fig. 1b). In Vegfr3ﬂox/ﬂox;R26-mTmG;Prox1-CreERT2 embryos,
GFP expression coincided with efﬁcient depletion of VEGFR3
protein (Fig. 1b, Supplementary Fig. 1), and reduced vessel
branching and diameter (Fig. 1b–d). Analysis of the sprouting
front at the dorsal midline of the skin revealed that most lym-
phatic vessel tips were occupied by GFP+ (i.e., gene targeted)
LECs in the control embryos. In contrast, the majority of
Vegfr3ﬂox/ﬂox vessels had a non-recombined VEGFR3+ cell at the
tip (Fig. 1b, e). The rare vessel tips composed of Vegfr3-deleted
cells showed a “blunted” morphology, in contrast to a “spiky”
morphology observed in most vessel tips in E17.5 control skin
(Fig. 1f). Consistent with the reduced ability of Vegfr3-deﬁcient
cells to contribute to vessel tips, the extension of lymphatic vessels
to the dorsal midline was compromised (Fig. 1g).
Next, we assessed the competence of LECs with homozygous or
heterozygous deletion of Vegfr3 to compete with wild-type
neighboring cells during embryonic lymphatic vessel sprouting.
Mosaic deletion of either one or two alleles of Vegfr3 was induced
by a single dose of 4-OHT at E13.5 (Fig. 1h) to label LECs
preferentially in the lateral skin18. The ability of gene targeted
GFP+ cells to migrate in the distally extending sprouts was
assessed at E16.5 (Fig. 1i). Both heterozygous and homozygous
Vegfr3 null cells failed to migrate within the sprouts to the dorsal
midline area (Fig. 1i, j). Together, the above results demonstrate
that VEGFR3 is indispensable for tip cell function during
embryonic dermal lymphatic vessel sprouting.
Early post-natal Vegfr3 deletion causes lymphatic hyperplasia.
To investigate if the mechanisms of lymphatic vessel sprouting
are conserved across stages of development, we studied the
dependence of early post-natal lymphatic development on
VEGFR3. We analyzed the lymphatic vasculature on the dorsal
side of the ear that forms by sprouting after post-natal day (P)4
and is remodeled from a primary vascular plexus into a network
of blind-ended lymphatic capillaries and valve-containing
collecting vessels between P12–P2119,20. Vegfr3 deletion was
induced prior to initiation of lymphatic sprouting by two con-
secutive administrations of Tamoxifen at P2 and P3 (Fig. 2a). We
considered that serum levels of the active metabolite 4-OHT are
maintained up to 72 h after each administration18,21, i.e., until P6.
GFP expression, correlating with VEGFR3 depletion in the
mutant mice (Supplementary Fig. 2), revealed an incomplete
contribution of the Vegfr3-deleted cells to the lymphatic vascu-
lature and their exclusion from the distal tips of lymphatic
capillaries (Fig. 2a, b). Surprisingly, a modest increase in vessel
hyperbranching was observed in the mutants (Fig. 2c). To max-
imize gene targeting efﬁciency, we administered Tamoxifen every
second day until P21. This unexpectedly resulted in a severely
hyperbranched lymphatic vessel network (Fig. 2a, c), a phenotype
opposite to that observed upon embryonic loss of Vegfr3
(Fig. 1a–g) or systemic inhibition of VEGFR3 or its ligands22.
Additional temporally controlled gene deletions showed that
three Tamoxifen administrations at P2, P4, and P6 were sufﬁcient
to induce efﬁcient gene targeting and vessel hyperbranching,
which was evident already at P15 (Fig. 2a, c). As expected, and
conﬁrming the LEC-autonomous nature of the phenotype, der-
mal blood vasculature was not affected in the mutants (Supple-
mentary Fig. 3a). A similar lymphatic vessel hyperbranching
phenotype was observed in the intestinal wall of mutant mice
(Supplementary Fig. 3b, c). We conclude that early post-natal
Vegfr3 deletion leads to lymphatic vessel hyperplasia during the
formation of the primary dermal vascular plexus in a critical post-
natal period of 2 weeks. This was further supported by the ﬁnding
that a single 4-OHT administration at P12, when the remodeling
of the dermal lymphatic vasculature of the ear begins19, did not
induce vessel hyperplasia despite efﬁcient VEGFR3 depletion
(Fig. 2a, Supplementary Fig. 2). Instead, a distinct phenotype
characterized by abnormal patterning of the distal lymphatic
capillary network was observed (Fig. 2a).
The excessive dermal lymphangiogenic growth and branching
observed upon early post-natal deletion of Vegfr3 closely
resembled the angiogenic hypersprouting phenotype in the
retinal vasculature resulting from endothelial Vegfr3 deletion7.
Blood vessel hyperplasia was linked to increased VEGFR2 protein
expression and signaling, thus implicating VEGFR3 as a negative
regulator of the VEGF-VEGFR2 pathway7,23. To test if increased
VEGFR2 signaling also contributes to Vegfr3 loss-induced
lymphatic vessel hyperplasia, we genetically deleted Vegfr2 in
combination with Vegfr3 using the Prox1-CreERT2. Loss of Vegfr2
did not cause an apparent phenotype (Fig. 2d–f, Supplementary
Fig. 4a–c). In addition, Vegfr2 deletion, using a 3-day (Fig. 2d–f)
or an extended 10-day Tamoxifen administration protocol
(Supplementary Fig. 4a–c), did not rescue, but rather exacerbated
the Vegfr3 mutant phenotype. These results suggest that in the
lymphatic vasculature, cell-autonomous regulation of VEGFR2 by
VEGFR3 does not explain vessel hyperplasia induced by the loss
of Vegfr3. This was further supported by unchanged VEGFR2
protein and messenger RNA (mRNA) expression in Vegfr3-
deleted LECs isolated from the mutant ears (Supplementary
Fig. 3 Lymphatic vascular hyperplasia in Vegfr3-deleted ears is driven by VEGF-C signaling. a Quantiﬁcation of blunt-ended vessels (lymphatic capillaries)
in 5 weeks old mice treated with Tamoxifen at P2, P4, and P6. Central region excludes 560 μm area (tip) from the edge of the ear. Bars represent mean (n
= 3–6 mice, as indicated) ± s.e.m. bWhole-mount immunoﬂuorescence of Vegfr3ﬂox/ﬂox;R26-mTmG;Prox1-CreERT2 ear skin showing vessel interconnections
(arrows) formed of non-targeted (GFP−) LYVE1+ (left) and VEGFR3+ (right) LECs. c Whole-mount immunoﬂuorescence of ear skin of 3 weeks old
Vegfr3ﬂox/ﬂox;R26-mTmG;Prox1-CreERT2 and Cre-negative littermate mice treated with Tamoxifen at P2, P4, and P6, and inhibitors of VEGF-C signaling (the
VEGF-C-trap VEGFR3-Ig, the VEGFR3 inhibitor MAZ51, or the VEGFR2 blocking antibody DC101). Quantiﬁcation of (d) vessel area and (e) branch points.
Bars represent mean (n= 3 (untreated groups) or n= 4 (treated groups) mice) ± s.e.m. f–h Visualization by whole-mount immunoﬂuorescence (arrows in
f) and quantiﬁcation of blunt-ended vessels in the (g) entire and (h) central region of the ear in Vegfr3ﬂox/ﬂox;R26-mTmG;Prox1-CreERT2 mice treated with
the VEGFR3 kinase inhibitor MAZ51. In g, h, bars represent mean (n= 3 (untreated) or n= 4 (MAZ51, DC101) mice) ± s.e.m. *P < 0.05, **P < 0.01, ***P <
0.001, ****P < 0.0001. Two-tailed unpaired Student’s t test (a, d, e, h). Scale bars: 200 µm (b, c, f). ns: not signiﬁcant
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Fig. 4d, e, Supplementary Fig. 5) and in Vegfr3-deﬁcient vessels
in vivo (Supplementary Fig. 4f).
VEGF-C drives lymphatic hyperplasia in Vegfr3-deleted ears.
Detailed characterization of the lymphatic phenotype in the
Vegfr3ﬂox;R26-mTmG;Prox1-CreERT2 ears revealed that the
number of blunt-ended lymphatic capillaries was signiﬁcantly
reduced in the central region of Vegfr3-deleted ears in compar-
ison to control ears (Fig. 3a), suggesting that abnormal anasto-
mosis of lymphatic capillaries contributes to the hyperbranching
phenotype. The phenotype was not altered when Vegfr2 was also
deleted (Fig. 3a). Notably, abnormal interconnections were pre-
dominantly formed by non-targeted LECs when Vegfr3 was
deleted alone (Fig. 3b) or in combination with Vegfr2 (Supple-
mentary Fig. 4g). This suggested that rather than acting in a cell-
autonomous manner, Vegfr3 deﬁciency induces abnormal beha-
vior of neighboring VEGFR3+ cells.
To assess the contribution of VEGF-C signaling to the
phenotype, due to its ability to stimulate non-targeted LECs, we
inhibited all VEGF-C signaling in the Vegfr3ﬂox/ﬂox;R26-mTmG;
Prox1-CreERT2 mutant and Cre− littermate control mice by
administering adeno-associated vectors (AAVs) encoding soluble
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VEGF-C-trap (AAV-Vegfr3-Ig)24. The relative contribution of
the two VEGF receptors in non-targeted LECs was further
investigated by treatment with the VEGFR2 blocking antibody
DC101 or the VEGFR3 kinase inhibitor MAZ51. To overcome
the requirement of VEGF-C signaling for LEC survival and
proliferation at early post-natal stages22, while achieving efﬁcient
inhibition during the critical period for the phenotype to develop
(Fig. 2c), we administered AAV-VEGFR3-Ig by intraperitoneal
injection at P10. As expected, control mice expressing VEGFR3-
Ig showed decreased growth of lymphatic vasculature in the ear
skin (Fig. 3c, d). In the Vegfr3ﬂox/ﬂox;R26-mTmG;Prox1-CreERT2
mutants, vessel hyperplasia was completely rescued and the
vasculature showed a similar reduction in growth as in the
control (Fig. 3c, d). Selective VEGFR3 inhibition from P7 did not
affect the ear vasculature in the control mice when analyzed at
P21 (Fig. 3c–e), but partially rescued the hyperbranching in 2 out
of 4 mutants (Fig. 3e). Interestingly, VEGFR3 inhibition
signiﬁcantly reduced vessel anastomosis and restored the number
of blunt-ended vessels in the central region of the ear (Fig. 3f–h).
In contrast, blocking VEGFR2 signaling inhibited Vegfr3 loss-
induced hyperplasia and excessive vessel branching (Fig. 3c–e),
but the number of blunt-ended vessels was not increased (Fig. 3g,
h). Together, these data show that VEGF-C, through signaling via
both VEGFR2 and VEGFR3 in the non-targeted LECs, drives
lymphatic vascular hyperplasia in the Vegfr3ﬂox/ﬂox;R26-mTmG;
Prox1-CreERT2 mutant skin.
Non-targeted LECs overproliferate in Vegfr3-deleted ears. To
further understand the cellular mechanism underlying the non-
cell-autonomous effect of Vegfr3 deletion, we focused our analysis
on the critical developmental stages when the phenotype ﬁrst
arises. Analysis of P11–P12 Vegfr3ﬂox;R26-mTmG;Prox1-CreERT2
homozygous mutant and heterozygous control ears showed a
similar overall recombination efﬁciency (i.e., GFP expression) in
the LEC population (Fig. 4a, b). However, analysis of the pro-
portion of LECs that had undergone a recent recombination
event, as revealed by perdurance of Tomato protein in Tomato-
gene-deleted GFP expressing cells, showed a striking difference
between the genotypes. In the heterozygous controls, the majority
of GFP+ LECs had lost Tomato by P11–P12 when Tamoxifen was
administered continuously from P2 onwards (Fig. 4a, b; indicated
in green). In contrast, most GFP+ LECs were Tomato+ in the
mutant ears (Fig. 4a, b; indicated in yellow). GFP expression and
loss of Tomato was conﬁrmed to correlate with genetic deletion of
Vegfr3 exon 1 and expression of Vegfr3 mRNA in LECs sorted
from mutant and control mice (Fig. 4c, Supplementary Fig. 5).
GFP+Tomato− LECs from Vegfr3ﬂox/ﬂox;R26-mTmG;Prox1-
CreERT2 mice showed reduced exon 1 copy number (relative
copy number 3.7 ± 2.3% (n= 6)) concomitant with reduced
Vegfr3 mRNA expression (relative expression 6.1 ± 4.2% (n= 4))
compared to Cre-negative controls (Fig. 4c). In contrast,
GFP−Tomato+ cells displayed variable levels of retained exon 1
(relative copy number 57.3 ± 23.8% (n= 6)) and Vegfr3 mRNA
(relative expression 46.4 ± 6.4% (n= 4)), suggesting loss of one
Vegfr3 allele. This was also observed in the GFP+Tomato+ LEC
(Fig. 4c). These data demonstrate that GFP+Tomato− LECs
represent fully recombined cells that have lost Vegfr3 expression,
while GFP−Tomato+ LECs retain, at the population level, Vegfr3
expression that corresponds to, or is higher than in Vegfr3 het-
erozygous LECs. The high proportion of Tomato+ cells in the
Cre-targeted GFP+ LEC population speciﬁcally in the homo-
zygous Vegfr3ﬂox/ﬂox mice further suggests selection against
complete loss of Vegfr3 and continuous initiation of recombina-
tion in non-targeted LECs.
To address how a pool of non-recombined LECs is maintained
in the mutant skin, we analyzed LEC proliferation in the
Vegfr3ﬂox;R26-mTmG;Prox1-CreERT2 ears by ﬂow cytometry.
Non-targeted LECs in the P11–P12 mutant ears showed a
signiﬁcantly higher EdU incorporation rate than targeted Vegfr3-
deﬁcient LECs, or LECs in control ears from Cre-negative
littermates (Fig. 4d, e). Heterozygous or homozygous loss of
Vegfr3 did not affect LEC proliferation under these conditions
(Fig. 4d, e). These results support a model (Fig. 4f) whereby
incomplete Cre-mediated targeting leads to selection of residual
non-targeted VEGFR3+ LECs to the tips of vessel sprouts
(Fig. 2b), and promotes their excessive proliferation (Fig. 4d) and
vascular anastomosis (Fig. 3a, b). Proliferation of non-targeted
LECs is subsequently sustained by a continuous induction of new
VEGFR3− neighbors through repeated Tamoxifen-induced
recombination during the critical post-natal period of 2 weeks
(Fig. 4f).
Post-natal role of VEGFR3 in LEC survival and proliferation.
Lymphatic hyperplasia caused by early post-natal Vegfr3 deletion
was unexpected considering the previously established pro-
lymphangiogenic role of VEGF-C signaling during embryo-
genesis14,16 (Fig. 1) and early post-natal development17,22. Con-
tinuous induction of Vegfr3 deletion in a new pool of non-
recombined LECs over a period of several days (Fig. 4) did not
allow the follow-up of the Vegfr3-deleted cells and their survival.
For this purpose, we performed a pulsed induction of Vegfr3
deletion by a single dose of 4-OHT that was administered during
the active lymphangiogenic growth phase at P7 or P10 (Supple-
mentary Fig. 6a). Two days after 4-OHT injection at P7 or P10,
we observed reduced proportion of GFP+ LECs in Vegfr3-deleted
compared to Vegfr3 heterozygous skin (Supplementary Fig. 6b, c).
This reduction could be referred to a selective reduction in GFP+
LECs that had lost Tomato (Supplementary Fig. 6b, d, e), sug-
gesting decreased survival of Vegfr3-deﬁcient LECs (Fig. 4c) at
this stage. Vegfr3-deﬁcient LECs also showed signiﬁcantly less
Fig. 4 Excessive proliferation of non-targeted VEGFR3+ LECs contributes to lymphatic vessel hyperplasia in Vegfr3-deleted ears. a, b Fluorescence-
activated cell sorting (FACS) evaluation of Tomato and GFP expression in Vegfr3ﬂox/+ and Vegfr3ﬂox/ﬂox;R26-mTmG;Prox1-CreERT2 LECs. Tamoxifen (150 µg)
was administered daily from P2 until harvest at P11–P12. Representative dot plots of GFP and Tomato expression, and histogram of Tomato expression in
GFP+ LECs are displayed with Cre− littermate as a control. In b, graph of combined results from two litters, showing the average distribution of cells
expressing Tomato only (red), GFP and Tomato (yellow), and GFP only (green). Dots show % of GFP+ LECs in individual mice, horizontal line represents
mean (n= 3 mice) ± s.e.m. c Vegfr3 exon1 deletion (left) and mRNA expression (right) in sorted Tomato+GFP− (red), Tomato+GFP+ (yellow), and Tomato
−GFP+ (green) LEC populations from P11–P14 Vegfr3ﬂox/ﬂox mutants (R3 ﬂ/ﬂ). Tamoxifen (150 µg) was administered at P2, P4, and P6. LECs from Cre−
mice (Ctrl) were used as controls with the average ΔCT cycle threshold as the reference value for relative quantiﬁcation. Horizontal line represents mean
(n= 3–6 mice). d, e 5-ethynyl-2'-deoxyuridine (EdU) incorporation evaluated by FACS analysis in LECs gated on Tomato and GFP expression, shown in
Fig. 3c. Representative histograms of EdU incorporation evaluated 24 h after injection and graph of combined results from two litters are shown in
e. Horizontal line represents mean (n= 3–5 mice). f Proposed model for the mechanism underlying post-natal Vegfr3 loss-induced lymphatic vessel
hyperplasia in the ear. Incomplete deletion of Vegfr3 promotes selection of non-targeted VEGFR3+ cells to the tips of vessel sprouts and their excessive
proliferation and vascular anastomosis. Proliferation of non-targeted VEGFR3+ cells is sustained by continuous induction of new VEGFR3- neighbors
through repeated Tamoxifen administrations during a critical post-natal period of 2 weeks. **P < 0.01, ***P < 0.001. Two-tailed unpaired Student’s t test
(e). ns: not signiﬁcant
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EdU incorporation than LECs in the control skin (Supplementary
Fig. 6f), resembling the situation in E15 thoracic skin (Supple-
mentary Fig. 6g). The requirement of VEGFR3 for LEC survival
and proliferation selectively during the early post-natal develop-
ment was corroborated by regression of the dermal lymphatic
vasculature in the ear when VEGF-C-trap was administered at P7
(Supplementary Fig. 6h), but not when administered after P1422.
Taken together, these results demonstrate that during the initial
growth of the lymphatic vascular plexus, VEGFR3 is required for
LEC survival and proliferation, both in the dorsal skin of embryos
(Fig. 1) and in the ear skin of early post-natal mice (Supple-
mentary Fig. 6).
VEGFR3− LECs induce proliferation of VEGFR3+ neighbors.
Next, we sought to understand the mechanism by which the
proliferation of non-targeted LECs is controlled in the Vegfr3-
deleted ears. In the retina, engulfment of VEGF by VEGFR2
expressing neurons controls VEGF levels to limit blood vessel
growth around neurons25. We asked if the inability of Vegfr3-
deﬁcient LECs to consume VEGF-C by receptor-mediated
endocytosis and subsequent degradation leads to excessive
VEGF-C levels and thereby contributes to vessel hyperplasia in
the mutant ears. Assessment of VEGF-C concentrations in tissue
homogenates by enzyme-linked immunosorbent assay (ELISA)
did not reveal differences between control and Vegfr3 mutant ears
(Fig. 5a). Vegfc or the related Vegfd mRNA was not increased
(Supplementary Fig. 7a, b), neither was the recruitment of mac-
rophages, which are major producers of VEGF-C and VEGF-D
in vivo26,27 (Supplementary Fig. 7c).
We then asked if Vegfr3-deleted LECs instead induce
proliferation of neighboring wild-type cells through direct
cell–cell communication. We isolated primary dermal LECs from
adult Vegfr3ﬂox/ﬂox;R26-mTmG;Prox1-CreERT2 mice and analyzed
cell proliferation after 4-OHT mediated Vegfr3 deletion in vitro.
GFP expression, which correlated with VEGFR3 depletion
(Fig. 5b), was observed in 11 ± 1.4 % (n= 6) of LECs 3–4 days
after 4-OHT treatment. Under conﬂuent contact-inhibited
conditions with low proliferation rate, most EdU+ wild-type
(WT) cells were in direct contact with VEGFR3-deleted (KO)
cells (Fig. 5c). To monitor the acute response of LECs to VEGFR3
deletion, we mixed cell tracker-labeled human dermal LECs
treated with control siRNA (siCTRL) with non-labeled LECs
treated with VEGFR3 siRNA (siVEGFR3) (Fig. 5d). Increasing
the proportion of siVEGFR3 cells in the co-cultures increased
proliferation of the siCTRL LECs (Fig. 5e). To ask if siCTRL cells
were more likely to proliferate when having immediate siVEGFR3
neighbors, we calculated the probability of random association.
Under conﬂuent culture conditions, LECs had an average of ﬁve
neighbors (5.2 ± 0.2, n= 172 LECs). In 80:20% siCTRL:
siVEGFR3 co-cultures, the predicted proportion of siCTRL LECs
that were in direct contact with at least one siVEGFR3 LEC was
therefore 67.2%, which was in agreement with our experimental
observation (63.4 ± 3.2%, n= 5) (Fig. 5f). However, the propor-
tion of EdU+ siCTRL cells that were in direct contact with
siVEGFR3 cells was signiﬁcantly higher (96.9 ± 6.9%, n= 5) than
expected, if the proliferating cells were randomly distributed
(Fig. 5f). Proliferation of siCTRL cells was not affected when co-
cultured without a direct contact with siVEGFR3 cells seeded on a
Transwell culture insert (Fig. 5g). These results demonstrate that
VEGFR3-deﬁcient LECs induce proliferation of neighboring WT
LECs in a cell-contact-dependent manner.
Low DLL4 in VEGFR3− LECs promotes proliferation in
neighbors. DLL4-Notch signaling is an important cell-contact-
mediated regulator of sprouting (lymph)angiogenesis4. In the
blood vasculature, DLL4 is induced by VEGF and VEGF-C in
ECs at the tips of vessel sprouts7,28,29. DLL4 activates Notch in
neighboring cells, which in most EC types and vascular beds has
been shown to result in cell cycle arrest113031,32. Conversely,
inhibition of DLL4 or NOTCH1 leads to excessive blood and
lymphatic vessel sprouting and EC proliferation28,29. Interest-
ingly, in the Drosophila tracheal system, which develops via
mechanisms analogous to the vertebrate vascular system, Notch
signaling additionally speciﬁes cells at the tips of the developing
tracheal branches by repressing ‘fusion cells’ (cells mediating
branch fusion) and promoting 'terminal cells' (cells extending
terminal branches) fate33–3536. We therefore hypothesized that
Notch signaling contributes to both excessive vascular anasto-
mosis and proliferation of VEGFR3+ LECs that are in contact
with VEGFR3− LECs. In agreement with this hypothesis, quan-
titative real-time PCR (qRT-PCR) analysis of human siRNA-
treated LECs revealed signiﬁcant downregulation of DLL4 in
VEGFR3-deﬁcient cells (Fig. 6a). The levels of NOTCH1 were
modestly lower, and the NOTCH1 target HEY1 was strongly
reduced, reﬂecting decreased Notch activation due to low DLL4
expression in these cells (Fig. 6a). Analysis of mouse LECs iso-
lated from the Vegfr3ﬂox/ﬂox;R26-mTmG;Prox1-CreERT2 ears
conﬁrmed Dll4 downregulation but unchanged Notch1 expression
in the Vegfr3 deﬁcient in comparison to Cre- control LECs
(Fig. 6b). Whole-mount immunoﬂuorescence further conﬁrmed
downregulation of DLL4 protein speciﬁcally in GFP+ (i.e.,
VEGFR3−) LECs in comparison to non-targeted GFP− (i.e.,
VEGFR3+) LECs in the mutant ears (Fig. 6c). Further analysis of
cells in mosaically targeted vasculature in vivo showed that Notch
signaling, as assessed by Hey1 expression, was downregulated in
both non-targeted VEGFR3+ (GFP−Tomato+) LECs and tar-
geted VEGFR3− (GFP+Tomato−) LECs from the Vegfr3ﬂox/ﬂox;
R26-mTmG;Prox1-CreERT2 mutant ears compared to LECs from
Cre− control mice (Fig. 6d). In addition, Efnb2, a previously
demonstrated target of DLL4-Notch1 signaling in the lymphatic
vasculature20, was strongly downregulated in the non-targeted
LECs (Fig. 6e). Higher expression of the proliferation marker
Ccnb1 conﬁrmed increased proliferation of the non-targeted
LECs (Fig. 6f).
To further investigate if LEC proliferation is affected by
decreased DLL4-Notch signaling, we cultured human LECs under
conﬂuent growth-inhibiting conditions in the presence of low (25
ng ml−1) VEGF-C stimulation. Wild-type LECs showed a low
proliferation rate, which was further reduced upon
VEGFR3 silencing (Fig. 7a, b). Inhibition of Notch signaling by
DAPT treatment increased proliferation of wild type but not
VEGFR3− LECs (Fig. 7a, b). Similarly, LECs treated with
NOTCH1 siRNA (siNOTCH1) (Fig. 7c) showed increased
proliferation in comparison to siCTRL cells (Fig. 7d). Although
Notch inhibition promoted proliferation in LECs cultured in
complete serum containing medium in the absence of VEGF-C,
the effect was more pronounced when VEGF-C was present
(Fig. 7d), suggesting the importance of VEGF-C-VEGFR3
signaling in this response. To investigate if mosaic loss of Notch
activation is sufﬁcient to phenocopy the effect of mosaic loss of
VEGFR3 on the proliferation of the neighboring cells, we
performed co-culture experiments using LECs treated with
siCTRL or siRNA against DLL4 (siDLL4) (Fig. 7e). As expected,
siDLL4 LECs showed increased proliferation in comparison to
siCTRL cells when cultured alone (Fig. 7f). In addition, increasing
the proportion of siDLL4 cells in the co-cultures increased the
proliferation of siCTRL LECs (Fig. 7f).
Together, the above results demonstrate that VEGFR3
mediated regulation of DLL4 controls Notch induced cell cycle
arrest in the LECs in a non-cell-autonomous manner. LECs with
low Notch respond by proliferation but only in the presence of
VEGFR3 (Fig. 7g).
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Discussion
VEGF-C signaling through its tyrosine kinase receptors VEGFR2
and VEGFR3 is the key regulator of embryonic and post-natal
lymphatic development14,17,22. Here we show, using conditional
Cre/loxP mediated gene deletion, that VEGFR3 is the major
VEGF-C receptor during embryonic lymphangiogenesis. LEC-
speciﬁc deletion of Vegfr3 in embryos led to dermal lymphatic
vessel hypoplasia and revealed an indispensable function of
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VEGFR3 for lymphatic endothelial tip cell function and vessel
sprouting. Our data further demonstrate that the embryonic
requirement of VEGFR3 for LEC survival and proliferation is
conserved in neonatal ear vasculature. Yet LEC-speciﬁc deletion
of VEGFR3 within the critical post-natal period of 2 weeks led to
dermal lymphatic vessel hyperplasia. Investigation of the
underlying cause of this unexpected phenotype uncovered a non-
cell-autonomous mechanism by which VEGFR3-deleted cells
induce excessive proliferation of residual VEGFR3+ LECs that
escaped Cre recombination.
In blood vascular ECs, loss of VEGFR3 results in increased
VEGFR2 levels and signaling[7,23], which was shown to drive
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hyperplasia of retinal vasculature in vivo upon genetic deletion of
Vegfr37. We found that the mechanism underlying lymphatic
vessel hyperplasia upon LEC-speciﬁc Vegfr3 deletion is different.
Namely, VEGFR2 levels were not altered in the Vegfr3-deleted
LECs, and LEC-speciﬁc genetic deletion of Vegfr2 did not rescue
lymphatic vessel hyperplasia induced by Vegfr3 loss. In contrast,
dermal lymphatic vessel hyperplasia was prevented by global
inhibition of VEGF-C signaling using the VEGF-C-trap, indi-
cating the dependence of the phenotype on VEGF-C signaling in
the non-targeted VEGFR3+ LECs. Global inhibition of VEGFR3
activity using the MAZ51 tyrosine kinase inhibitor in the same
setting inhibited abnormal lymphatic vessel anastomosis, while
inhibition of VEGFR2 function using the blocking antibody
DC101 reduced vessel hyperbranching. These data suggest spe-
ciﬁc and synergistic functions of VEGFR2 and VEGFR3 in
driving the abnormal VEGF-C-driven behavior of the non-
targeted VEGFR3+ LECs that are in contact with VEGFR3−
LECs.
Our results should, however, be interpreted with some caution
since it is not possible to ensure complete or equal inhibition of
the two receptors with the inhibitors used. That MAZ51 did not
have an apparent effect on wild-type vasculature at P21 indeed
suggests that the inhibitor does not fully inhibit VEGFR3 activity.
Another consideration is that while MAZ51 targets only the non-
recombined VEGFR3+ cells in the mutant skin, VEGF-C-trap
and DC101 target both the recombined VEGFR3− and non-
recombined VEGFR3+ LECs by inhibiting VEGFR2 signaling.
Although LEC-speciﬁc deletion of Vegfr2 alone or in combination
with Vegfr3 did not indicate a function for VEGFR2 in the LECs,
DC101 slightly reduced lymphatic growth in wild-type mice. It is
thus not possible to exclude a minor role for VEGFR2 in lym-
phatic development or in the VEGFR3-deleted LECs, because of,
e.g., slow kinetics of VEGFR2 depletion in the genetic mutants.
Post-natal LEC-speciﬁc genetic deletion of Vegfr3 led to
hyperplasia of lymphatic vasculature both in the skin and in the
intestinal wall. The process by which VEGFR3− LECs non-cell-
autonomously regulate lymphatic vessel growth by inducing
proliferation of non-targeted VEGFR3+ LECs through cell-
contact-dependent reduction in Notch signaling is however
unlikely to occur in every tissue with active VEGF-C-dependent
lymphangiogenesis. It is possible that lymphatic vascular beds
that form through a plexus intermediate via repeated cycles of
vessel sprouting and anastomosis are particularly sensitive to
aberrations in Notch signaling, based on the established function
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of this pathway in controlling similar processes in the blood
vasculature4,37. Intriguingly, previous studies have revealed
context-dependent roles of Notch signaling in the lymphatic
vasculature, whereby inhibition of Notch signaling can have
opposite effects depending on the tissue and developmental stage.
For example, inhibition of DLL4-Notch1 signaling inhibits der-
mal lymphatic vessel growth and sprouting in neonatal mice20,
but promotes vessel hyperplasia in adult mouse skin29. Interest-
ingly, inhibition of VEGF-C signaling blocks lymphatic vessel
growth and induces regression during embryonic and ear post-
natal development, but not after 2 weeks of age16,22. Our data
showing that VEGFR3 is an upstream regulator of DLL4 is thus
consistent with the early dependence of lymphatic growth on
DLL4-Notch1 signaling. The later switch of LECs to become
independent of VEGF-C for their survival, with the exception of
meningeal lymphatic vessels38, may be due to changes in matrix-
dependent signals or processes involved in vascular plexus for-
mation (initial plexus formation vs. remodeling). It should be
noted that different approaches of inhibiting pathway activity
(genetic deletion vs. soluble inhibitor; mosaic vs. global) may
result in different outcomes, which makes comparison of phe-
notypes difﬁcult.
Our results do not fully explain why Vegfr3 deletion induces
lymphatic vessel hyperplasia and hyperproliferation of non-
targeted LECs in early post-natal skin but not in embryonic skin.
Different kinetics of vascular plexus formation, but also the
kinetics of gene deletion18,21 in the two situations (4-OHT—fast
kinetics in embryos vs. Tamoxifen—slower kinetics in neonatal
mice) may affect the outcome that is determined by a balance
between cell-autonomous and non-cell-autonomous effects of
Vegfr3 deletion. In the embryo the primitive dermal vascular
plexus forms within 2–3 days, but in the post-natal ear, this
process takes 10–12 days. It is possible that during the rapid
expansion of embryonic vasculature the cell-autonomous effect of
Vegfr3 deletion on LEC proliferation and survival dominates.
Another possibility is that a speciﬁc subset of LECs in the early
post-natal vasculature are not efﬁciently targeted by the Prox1-
CreERT2, allowing for a sufﬁcient number of LECs to escape
recombination and respond to VEGFR3− neighbors by pro-
liferation. The observed efﬁcient Prox1-CreERT2 driven recom-
bination in wild-type vasculature does not suggest that this is the
case, however, such a scenario may become evident only when
non-targeted cells show a selective growth advantage.
The established view on sprouting angiogenesis places tip cells
exhibiting high VEGFR2 activation and DLL4 expression as the
initiators of the molecular and cellular processes of normal and
pathological vessel sprouting. We show that LECs with low
VEGFR3 are capable of promoting the formation of new vessel
sprouts and severe lymphatic vessel hyperplasia by stimulating
proliferation and vascular anastomosis in neighboring LECs in a
cell-contact-dependent manner. In addition to providing induc-
tive signals for vascular morphogenesis, such an unanticipated
non-cell-autonomous mechanism of driving tissue growth may
contribute to hyperplastic pathologies in the vasculature and in
other tissues. For example, it is not known if ECs carrying
somatic mutations underlying vascular malformations can engage
normal ECs for growth during lesion formation through non-cell-
autonomous mechanisms, but the reported low frequency of
mutant cells present in the affected tissue suggests this
possibility39.
The phenomenon we describe here by which a mosaic loss/
inhibition of a growth promoting pathway can unexpectedly
promote tissue growth through non-cell-autonomous effects can
be envisaged to apply to any tissue and growth promoting sig-
naling pathway. Recently, such a concept has emerged in cancer,
where interactions between different subclones of tumor cells
promote tumor progression40,41. It is also recognized that this
clonal cooperation can have a profound effect on therapeutic
outcomes, thus the identiﬁcation of non-cell-autonomous driver
subclones that promote tumor growth by inﬂuencing nearby
populations is critical. Since a major problem of therapeutic
approaches such as siRNA nanovectors42,43 is an incomplete
delivery to the target cell population, leading to generation of
subclones with heterogeneous expression of the target gene,
understanding of non-cell-autonomous effects will be an impor-
tant consideration for future studies.
Our data highlight challenges with interpreting phenotypes
from conditional Cre/loxP mouse models. When the studied gene
is critically required for a particular cellular process, cells that
escape Cre recombination obtain a selective advantage. The
observation that gene-deleted cells are not competent to con-
tribute to a particular process or tissue structure may reveal
indispensable functions for proteins. This is demonstrated by the
failure of ECs lacking NRP144 or VEGFR3 (this study) to lead the
sprouts of blood or lymphatic vessels, respectively. However, if
the contribution of non-recombined cells selectively in the
mutant tissues is not recognized, gene functions may be over-
looked. Our study also demonstrates a new concept that Cre-
targeted cells can drive abnormal processes through non-cell-
autonomous effects. Repeated induction of Vegfr3 deletion in a
new pool of non-targeted cells was critical for the development of
lymphatic hyperplasia in the present study. This can be explained
by the need for direct cell–cell interactions between targeted and
non-targeted cells, which after a pulsed Cre induction are not
expected to be maintained during the dynamic sprouting process
due to the selective survival, expansion, and migratory advantage
of the non-targeted cells. It is important to note that even in the
absence of repeated administrations of Tamoxifen, high serum
levels of the active metabolite 4-OHT are maintained for up to 72
h, compared to a faster 24 h clearance of administered 4-
OHT18,21. Depending on the dose, recombination has been
shown to occur weeks after the last Tamoxifen administration45.
Therefore, characterization of Cre-dependent phenotypes should
ideally take into account the kinetics of gene deletion (and protein
depletion), genotype-speciﬁc cell selection, and non-cell-
autonomous effects that may be at play.
In conclusion, we show that VEGFR3 regulates sprouting
lymphangiogenesis through cell-autonomous and non-cell-
autonomous mechanisms. Unexpectedly, VEGFR3− LECs non-
cell-autonomously drive abnormal lymphatic vessel anastomosis
and hyperplasia in LEC-speciﬁc Vegfr3 knock-out mice by lateral
induction of cell proliferation and vessel anastomosis in the
neighboring VEGFR3+ LECs that escaped Cre recombination.
The ﬁnding that heterogeneous inhibition of a growth promoting
signaling pathway promotes vascular hyperplasia has important
implications for the understanding of mechanisms of develop-
mental and pathological tissue growth.
Methods
Mice. R26-mTmG mice46 were obtained from the Jackson Laboratory. Prox1-
CreERT247, Vegfr3ﬂox48, and Vegfr2ﬂox49 lines were described previously. Vegfr2+/−
mice were generated by crossing Vegfr2ﬂox with the PGK-Cre mice, followed by
removal of the Cre transgene by crossing with C57BL/6J mice. All mice were
maintained on a C57BL/6J genetic background. For staging of embryos, the
morning of vaginal plug detection was considered E0. For induction of Cre
recombination, 4-hydroxytamoxifen (4-OHT), dissolved in peanut oil (10 mgml
−1), was administered to pregnant females by intraperitoneal injections as indi-
cated in ﬁgures and/or legends. For neonatal deletion, Tamoxifen or 4-OHT,
dissolved in acetone (10 mgml−1), was applied topically to abdominal skin using
the indicated doses and regimes. Alternatively, 4-OHT dissolved in ethanol (25 mg
ml−1) was given intraperitoneally (2 μl). For AAV transduction, pups were injected
intraperitoneally at P10 with 5 × 1010 viral particles in 8.4 µl of a recombinant
AAV9 encoding the ligand binding domains 1–4 of VEGFR3, fused to the IgG Fc
domain (AAV9-mVEGFR31–4-Ig;24). For treatment with blocking antibody or
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inhibitor, pups were injected intraperitoneally every second day from P7 to P17
with 40 mg kg−1 VEGFR2 blocking antibody DC101 (BE0060, BioXcell) or 10 mg
kg−1 VEGFR3 inhibitor MAZ51 (676492, Calbiochem). To assess cell proliferation
in vivo, pups were administered with 100 µl of EdU (5 mgml−1) by subcutaneous
injection using the indicated regimes. Crosses were performed until a minimum of
three control or mutant animals from a minimum of two litters were obtained.
Experimental procedures were approved by the Uppsala Laboratory Animal Ethical
Committee.
Primary LEC culture. Human primary dermal lymphatic ECs (HDLEC from
juvenile foreskin, cat. no. C12216) were obtained from PromoCell. Cells were
seeded on bovine Fibronectin (F1141, Sigma) coated dishes in complete ECGMV2
medium (PromoCell) supplemented with 25 ng ml−1 of VEGF-C (2179-VC, R&D
Systems) and used after three to four passages. For assessing proliferation, cells
were cultured under conﬂuent contact-inhibited conditions (6.3 × 104 cells per
cm2). Murine primary dermal lymphatic ECs were isolated from the tail skin of
6 weeks old Vegfr3ﬂox/ﬂox;R26-mTmG;Prox1-CreERT2 female by sequential selection
with PECAM1 (Mec13.3, Pharmingen) and LYVE1 (Aly7, Abnova) antibodies
bound to Dynabeads, as described previously50. Mouse LECs were cultured on
0.5% gelatin-coated dishes and passaged 1:3 after 4 days. In vitro gene deletion was
induced by adding 1 µM 4-OHT (H7904, Sigma) to the culture medium. Notch
signaling was inhibited by 24 h treatment with 10 µM DAPT (CAS 208255-80-5,
Calbiochem). All cells were cultured at 37 °C in a humidiﬁed atmosphere with
5% CO2.
RNA interference. Human dermal LECs were transfected with siRNA against
VEGFR3 (SI02225454, Qiagen), NOTCH1 (SI00119028, Qiagen), DLL4 (L-010490,
Dharmacon), or control siRNA (1027281, Qiagen) using Lipofectamine 2000
(Invitrogen) for 12 h before replacing the transfection medium with culture
medium. For VEGFR3 siRNA, cells were re-transfected after 12 h followed by re-
seeding or collecting 12 h later.
Immunoﬂuorescence. Whole-mount immunoﬂuorescence was done as previously
described18,19 with minor modiﬁcations. Two dermal sides of ears were separated
by forceps and the dorsal side was processed for staining. A small piece of intestine
(jejunum) was carefully collected and pinned down with outer side upward. First,
tissue was ﬁxed in 4% paraformaldehyde (PFA), permeabilized in 0.3% Triton X-
100 in PBS (PBST), and blocked in PBST plus 3% milk. Primary antibodies were
incubated at 4 °C overnight in blocking buffer. After washing in PBST, the samples
were incubated with ﬂuorescence-conjugated secondary antibodies in blocking
buffer before further washing and mounting in Mowiol. Cells grown on 48-well
plate were ﬁxed with 4% PFA at room temperature (RT) for 20 min, washed twice
with PBS and permeabilized in 0.5% Triton X-100 in PBS for 5 min, and blocked in
PBST plus 2% BSA for 1 h. Cells were incubated with primary antibodies diluted in
the blocking buffer at RT for 1 h. After washing three times with PBS+ 0.2% BSA,
the cells were incubated with ﬂuorescence-conjugated secondary antibodies at RT
for 45 min, followed by staining with DAPI (D9542, Sigma, 1:1000) for 5 min, and
ﬁxing with 4% PFA for 4 min before further washing and mounting in Mowiol. The
following antibodies were used for immunoﬂuorescence: chicken anti-GFP
(ab13970, Abcam, 1:500), hamster anti-mouse Podoplanin (clone 8.1.1, Develop-
mental Studies Hybridoma Bank, 1:200), rat anti-mouse PECAM1 (553370, BD
Biosciences, 1:1000), rabbit anti-mouse LYVE1 (103-PA50AG, Reliatech, 1:200),
α-smooth muscle actin (SMA)-Cy3 (C6198, Sigma, 1:300), rat anti-mouse Endo-
mucin (sc-65495, Santa Cruz, 1:200), rat anti-mouse F4/80 (MCA497GA, AbD
Serotec, 1:200), rat anti-mouse LYVE1 (MAB2125), goat anti-mouse Nrp2
(AF567), goat anti-mouse DLL4 (AF1389), goat anti-mouse VEGFR2 (AF644),
goat anti-mouse VEGFR3 (AF743; all from R&D Systems and 1:200). Secondary
antibodies conjugated to Cy3, AlexaFluor 488 or 647 were obtained from Jackson
ImmunoResearch (1:300). To assess cell proliferation in vitro, Click-iT EdU Alexa
Fluor 647 Imaging kit (C10340, Thermo Fisher Scientiﬁc) was used. Primary
mouse or human LECs were incubated with a ﬁnal concentration of 10 μM EdU at
37 °C for indicated time periods, followed by washing and EdU detection according
to manufacturer’s instructions.
Flow cytometry. Ear skin was digested in 5–10 mgml−1 Collagenase IV (Life
Technologies) and 0.2 mgml−1 DNase I (Roche) in PBS plus 0.5% fetal calf serum
(FCS) (Gibco) at 37 °C for 20–30 min. Digested samples were quenched by adding
2 mM EDTA and ﬁltered through a 70 μm nylon ﬁlter (BD Biosciences). Cells were
washed with FACS buffer (PBS, 0.5% FCS, 2 mM EDTA) and immediately pro-
cessed for staining in 96-well plates. Fc receptor binding was blocked by rat anti-
mouse CD16/CD32 (93) (eBioscience, 1:100). For RNA cell sorting, ECs were
enriched using CD31/PECAM1 magnetic microbeads (Miltenyi Biotech) on a MS
column according to the manufacturer’s instructions. Cells were stained using a
combination of anti-CD31/PECAM-1 (390) PE-Cy7 (1:300), anti-podoplanin
(PDPN) (eBio8.1.1) eF660 (1:100), and biotinylated anti-VEGFR2 (Avas12a1)
(1:50) (all from eBioscience). VEGFR2 was detected by adding SA-PERCP-Cy5.5
(eBioscience, 1:300) in a second staining step. Dump channel included markers to
exclude immune cells using anti-CD45 (30-F11); myeloid cells using anti-CD11b
(M1/70) and red blood cells using anti-TER-119 (TER-119) antibodies; all diluted
1:50 and conjugated to eF450 (eBioscience); together with Sytox blue (Life
Technologies) for dead cell exclusion. LECs were gated in three steps; (1)
PECAM1high, dump channel− cells, (2) PECAM1+, VEGFR2+ (ECs), (3) PDPN+
(LECs). LECs were subsequently sorted based on GFP and Tomato expression.
Sorting was performed on a FACS Aria III with the FACSDiva software (BD
Biosciences) using a 100 µm nozzle, 20–25 pounds per square inch (psi), with a
highly pure sorting modality (four-way purity sorting), and an acquisition rate of
500–1000 events per s. A total of 500–1000 cells were sorted directly into RLT
buffer with beta-mercaptoethanol and immediately processed for RNA extraction
using the Qiagen micro kit plus. To assess proliferation, cells were stained with
ﬂuorophores compatible with the Click-it EdU AF647 ﬂow cytometry kit (Thermo
Fisher Scientiﬁc) in ﬁve steps: (1) anti-CD45 (30-F11) (1:50) and anti-CD11b (M1/
70) (1:50) both conjugated with Percp-Cy5.5 and anti-CD31/PECAM-1 (390)
BV510 (1:50); (2) LIVE/DEAD ﬁxable near-infrared dead cell stain kit (Invitrogen);
(3) ﬁxation and Click-it reaction according to the manufacturer’s instructions; (4)
chicken anti-GFP (13970, Abcam, 1:200); (5) donkey anti-chicken AF488 (Jackson
ImmunoResearch, 1:300) and rat anti-mouse PDPN (eBio8.1.1) PE-Cy7 (1:300).
LECs were gated in three steps: (1) PECAM1+, cell death− (live ECs); (2)
PECAM1high, CD45/CD11b− (EC pure); (3) PDPN+ (LEC). LECs were further
analyzed for GFP and Tomato expression and EdU labeling. In some experiments,
an additional staining step for VEGFR2 was included as described for the sorting of
cells before ﬁxation and Click-it reaction. In this case, ﬂuorophores for detection of
CD11b and CD45 were exchanged to AF450. Data were processed using FlowJo
software (TreeStar). Single cells were gated using FSC-A/SSC-A followed by
FSC-H/FSC-W and SSC-H/SSC-W in all experiments. The anti-rat/hamster
compensation bead kit (Thermo Fisher Scientiﬁc) was used for compensation
controls with addition of GFP+, Tomato+, and LIVE/DEAD ﬁxable near-IR dead
cell stained cells.
Image acquisition and quantiﬁcation. Images were acquired using Zeiss LSM 780
confocal microscope and Zen software (Fig. 1b), or Leica SP8 confocal microscope
with HC PL APO CS 10×/0.4 DRY or HL PL APO 40×/1.1W motCORR CS2
objective and LAS X software. All confocal images represent maximum intensity
projections of Z-stacks of single tile or multiple tile scan images.
Quantiﬁcation of lymphatic vessel parameters (branching, diameter, tip cell
occupancy, number of cells and blunt-ended vessels, avascular midline area, vessel
area) was done using maximum intensity projection images of tile scanned
E17.5 skins (xy= 3400 × 1700 μm, upper thoracic region); P14, P21 or 5-week ear
skin (xy= 3260 × 2200 μm at the tip of the ear) or P21 intestinal wall (xy= 2050 ×
2050 μm); n= 3–10 mice as indicated in the ﬁgures and/or ﬁgure legends. All
branch points in each image were marked using Photoshop CS6 software and
counted manually. Vessel diameter was determined by measuring the thickest part
of each vessel segment in between branch points (n= 30 measurements per skin)
and mean value was plotted for each embryo. For measurement of the distance of
lymphatic sprouts from the midline (i.e., avascular midline), dorsal midline was
marked with a line and six to eight measurements, three to four on each side of the
midline, were taken from each image using the LSM image browser (Zeiss) and
mean value was plotted for each embryo. Lymphatic vessels closest to the midline
were included. GFP+ cells in the midline (area depicted in Fig. 1i) were counted
manually. The distinction between individual GFP+ cells was made based on
staining with nuclear marker PROX1 or membrane-bound GFP signal marking the
borders between adjacent GFP+ cells. Blunt-ended vessels were counted manually
in the tip (560 μm from the edge of the ear) and central regions of the ear. For
quantiﬁcation of tip cell occupancy by Cre-targeted cells, presence of GFP+ cells
were counted manually in vessel tips visualized by PDPN (ear) and Nrp2 or
VEGFR3 (embryonic skin) staining using Image J or Adobe Photoshop software. In
the ear, lymphatic vessels closest to the edge of the ear tip were included. Vessel
area was determined as % of LYVE1+ or VEGFR3+ area of the total area using
Image J software. All quantiﬁcations were done with littermate controls, which
were either heterozygous Vegfr3ﬂox/+;Prox1-CreERT2 mice or Cre-negative
Vegfr3ﬂox/ﬂox or Vegfr3ﬂox/+ mice as indicated in the ﬁgures and/or ﬁgure legends.
In some experiments, wild-type controls were additionally generated as separate
litters of R26-mTmG;Prox1-CreERT2 (Fig. 1c–g) or C57BL/6J (Fig. 2c, e, f, Fig. 3a,
and Supplementary Fig. 4c) mice.
Quantiﬁcation of proliferation and association of WT LECs with Vegfr3 KO
LECs (mouse), and siCTRL with siVEGFR3/siDLL4/siNOTCH1 LECs (human)
in vitro was done using maximum intensity projection images of tile scans (xy=
1720 × 1720 μm). Cell proliferation was determined as % EdU+ cells of all Hoechst
+ nuclei using Image J software. To assess association of proliferating WT/siCTRL
LECs with Vegfr3 KO/ siVEGFR3/ siDLL4 LECs, the former were labeled with cell
tracer Green CMFDA dye according to the manufacturer’s instructions (C2925,
Thermo Fisher Scientiﬁc) 24 h before co-culture. All EdU+ and Hoechst+WT cells
that had a direct contact with Vegfr3 KO/siVEGFR3/siDLL4 cells were marked
using Photoshop CS6 software and counted manually.
Western blot. LECs were washed with PBS and scraped from the dish with heated
lysis buffer (70 mM Tris-HCl, pH 6.8, 4.3% SDS, 14.5% glycerol), and homogenized
with a syringe (1 ml with a 27 G needle) for eight times. After centrifugation,
supernatants were collected followed by addition of bromophenol blue and 5% β-
mercaptoethanol and boiling at 95 °C for 5 min. Equal amounts of total cell lysates
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were separated in 4-20% gradient polyacrylamide gels (Invitrogen), transferred to
polyvinylidene diﬂuoride membrane (PVDF; Thermo Fisher Scientiﬁc) and probed
with antibodies as indicated. Proteins were detected using mouse anti-human
VEGFR3 (clone 9D9, MAB3757, Millipore, 1:50), rabbit anti-human Cleaved
NOTCH1 (Val1744) (#4147, CST, 1:1000), rabbit anti-human DLL4 (#2589, CST,
1:1000), rabbit anti-human GAPDH (#2118, CST, 1:3000) and mouse anti-human
α-tubulin (T5168, Sigma, 1:1000) and visualized by using an ECL chemilumines-
cent substrate reagent (Invitrogen). Full blots are shown in Supplementary Fig. 8.
qRT-PCR analysis. Total RNA was isolated from human dermal LECs using
RNeasy Mini kit (Qiagen) and from sorted LECs using RNeasy Micro plus kit
(Qiagen). Complementary DNA (cDNA) was synthesized using Superscript VILO
Master Mix (Invitrogen). cDNA was pre-ampliﬁed using TaqMan PreAmp Master
Mix (Applied Biosystem), and analyzed by real-time quantitative PCR (qRT-PCR)
(StepOne Plus system, Applied Biosystems) using TaqMan gene expression assays
and TaqMan gene expression Master Mix (Applied Biosystems). Relative quanti-
ﬁcations of gene expression were performed using the comparative cycle threshold
method (ΔCT) with GAPDH as the reference gene. TaqMan Assays used for
human LECs were as followed: VEGFR3 (Hs00176607_m1), DLL4
(Hs00184092_m1), NOTCH1 (Hs01062014_m1), HEY1 (Hs01114113_m1),
GAPDH (Hs02786624_g1). TaqMan assays used for mouse LECs were: Vegfr2
(Mm01222421_m1), Vegfr3 (Mm01292604_m1), Dll4 (Mm00444619_m1), Notch1
(Mm00627185_m1), Efnb2 (Mm00438670_m1), Hey1 (Mm00468865_m1), Ccnb1
(Mm03053893_gH), Vegfc (Mm00437310_m1), Vegfd (Figf) (Mm01131929_m1),
Gapdh (Mm99999915_g1). The values represent average relative gene expression.
The average ΔCT value for control LECs was used for normalization unless spe-
ciﬁed differently.
Genotyping of sorted LECs. Primers and probe covering exon 1 of Vegfr3 were
designed: exon1F1: GCTGAACCTGCGCCTGTG; exon1R1: TTAAGCGG-
GAGCGGAGGTTG and probe exon1P1: TGAGCGCCCGGGCCACAGCC, giving
an amplicon size of 82 bp. The probe was labeled with 5′Fam–3′Tamra. A total of
100–300 LECs were sorted by ﬂow cytometry (as described above) into lysis buffer
containing 25 mM NaOH and 0.2 mM EDTA (Sigma), and heated for 10 min at 95
°C. The pH was neutralized by adding 40 mM Tris-HCL (Sigma). Lysed cells were
used as template for real-time qPCR, using 250 nM probe and 300 nM primers for
exon1 (StepOne Plus system, Applied Biosystems) with TaqMan gene expression
Master Mix (Applied Biosystems). Relative quantiﬁcations were performed using
the comparative CT method (ΔCT) with Gapdh (Mm99999915_g1, genomic DNA
compatible) (Applied Biosystems) as the reference gene. The average ΔCT for Cre-
negative cells was used as the reference value for relative quantiﬁcation.
ELISA. A stripe of tissue in the middle of the ear was homogenized in modiﬁed
RIPA buffer as described51 using a plastic pestle followed by centrifugation for 5
min at 5000×g. Supernatant was collected and total protein concentration was
measured by BCA protein assay kit (Thermo Fisher Scientiﬁc). Three micrograms
of total protein was used for ELISA assay using mouse VEGF-C kit (CUSABIO).
Statistical analysis. GraphPad Prism was used for graphic presentation and sta-
tistical analysis of the data. Data between two groups were compared with unpaired
two-tailed Student’s t test or Fisher’s exact test, assuming equal variance. Com-
parison between multiple groups (Fig. 7d) was done using one-way ANOVA with
Tukey’s post hoc test. Differences were considered statistically signiﬁcant when P <
0.05. The experiments were not randomized. No blinding was done in the analysis
and quantiﬁcations.
Data availability. All relevant data are available from the corresponding author
upon request.
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